EDSA News and Press, Edesa Biotech Inc. From 01/20/21

Par Nijhawan, CEO of Edesa Biotech ([[EDSA]] +15.5%) is scheduled to join a panel discussion on COVID-19 organized by Clinical Trials Ontario in collaboration with the Bureau du Québec à Toronto and the Canadian and International Innovation Partnerships Directorate.In the ...

Caladrius Biosciences (CLBS) +120%.Aptorum Group (APM) +61% as Canada approves early-stage infection drug trial.Steel Connect (STCN) +54%.Dare Bioscience (DARE) +39%.ENDRA Life Sciences (NDRA) +36%.Lineage Cell Therapeutics (LCTX) +34%.Inuvo (INUV) +33%.eMagin Corporation (EMAN) +28...

TORONTO, ON / ACCESSWIRE / January 20, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event organized by Clinical Trials Ontario in collaboration wi...

TORONTO, ON / ACCESSWIRE / January 11, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from the Ministry of Health (INVIMA) in Colombia to expand the clinical trial of its investigational drug EB05 in hospitalized COVID-19 patients....

TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijhawan, providing a review of 2020. Dear Fellow Shareholders, It would be difficult to begin...

Nabriva Therapeutics NBRV -30% after priced $15M public offering.Aytu BioScience (AYTU) -25% on raising 'bought deal' offering to $25M.Immutep (IMMP) -24%.Professional Diversity Network (IPDN) -24%.SELLAS Life Sciences Group SLS -21% after announcing positiv...

Edesa Biotech (EDSA): FY GAAP EPS of -$0.74 misses by $0.04.Revenue of $0.33M beats by $0.02M.Press Release For further details see: Edesa Biotech EPS misses by $0.04, beats on revenue

TORONTO, ON / ACCESSWIRE / December 7, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the fiscal year ended September 30, 2020 and provided an update on its business. During the fiscal year, Edesa added two Phase 2-...

TORONTO, ON / ACCESSWIRE / November 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced that the first patient has been enrolled in a Phase 2/Phase3 clinical trial evaluating the company's investigational drug, EB05, as a therapy for hosp...

TORONTO, ON / ACCESSWIRE / November 6, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to present at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020 at 12:...